Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
EOM Pharmaceuticals Holdings, Inc. (IMUC)
USD0.15
-0.05 (-25.00%)
US OTC Healthcare Biotechnology
Address
136 Summit Avenue 7645
Montvale, NJ, US
Montvale, NJ, US
CEO
Irach Taraporewala
Website
eompharma.com
IPO
2021-01-08
CIK 822411 ISIN US4525364026
Description
EOM Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medications. These treatments hold the potential to revolutionize existing therapeutic approaches. Among its key drug candidates currently undergoing development are EOM613 and EOM147. Established on March 20, 1987, the company maintains its corporate headquarters in Montvale, New Jersey.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.15
-0.05 (-25.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7.4K
Beta
0.34
Float Shares
112.95M
Free Float %
99.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.51% | +8.70% | +47.06% | +55.86% | -37.50% | +76.06% | +9.75% | -63.24% | -79.84% | -73.40% | -73.40% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Hold
Price Targets & DCF
Current price
0.15
Ratings Trend (MoM)
0% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-30.31
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+7.3% Q4'22: +94.4% (vs Q4'21)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q4'22: +111.0% (vs Q4'21)
-
Share dilution Biotechnology: -3.4%+9.9% Q4'22: +182.2% (vs Q4'21)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.96× Q4'22: -2.75× (vs Q4'21)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
|---|---|
| Revenue |
4.30M
est.
|
| EBITDA |
—
est.
|
| EBIT |
—
est.
|
| Net Income |
—
est.
|
| SGA |
—
est.
|
| EPS |
—
est.
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-19.04M
OE per share TTM
-86.51
Owner's Yield
-120.40%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
155.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
18
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 13G | 5.00M | 5.70% | — | 5.00M | — | 5.00M | CO | Cayman Islands | 2015-02-20 | ↗ |
| 2 | Sabby Healthcare Master Fund, Ltd. | 5.00M | 5.54% | — | 5.00M | — | 5.00M | CO | Cayman Islands | 2015-02-19 | ↗ |
| 3 | ACM Capital Partners, LLC | 2.82M | 7.28% | — | 2.82M | — | 2.82M | HC | USA | 2012-01-20 | ↗ |
| 4 | Ayer Capital Management, LP | 2.82M | 7.28% | — | 2.82M | — | 2.82M | IA | USA | 2012-01-20 | ↗ |
| 5 | Jay Venkatesan | 2.82M | 7.28% | — | 2.82M | — | 2.82M | HC | USA | 2012-01-20 | ↗ |
| 6 | Lapides Asset Management, LLC | 1.21M | 5.10% | 1.68M | — | 1.68M | — | IA | Delaware | 2010-05-05 | ↗ |
| 7 | Patricia Peizer | 1.03M | 9.90% | 1.03M | — | 1.03M | — | IN | OR PLACE OF ORGANIZATION | 2011-02-14 | ↗ |
| 8 | Socius CG II, Ltd. | 1.03M | 9.90% | 1.03M | — | 1.03M | — | OO | OR PLACE OF ORGANIZATION | 2011-02-14 | ↗ |
| 9 | Socius Capital Group, LLC | 1.03M | 9.90% | 1.03M | — | 1.03M | — | HC | OR PLACE OF ORGANIZATION | 2011-02-14 | ↗ |
| 10 | Terren S. Peizer | 1.03M | 9.90% | 1.03M | — | 1.03M | — | IN | OR PLACE OF ORGANIZATION | 2011-02-14 | ↗ |
| 11 | Daniel B. Asher | 391.4K | 1.10% | — | 391.4K | — | 391.4K | HC, IN | United States of America | 2018-02-13 | ↗ |
| 12 | Intracoastal Capital LLC | 391.4K | 1.10% | — | 391.4K | — | 391.4K | OO | United States of America | 2018-02-13 | ↗ |
| 13 | Mitchell P. Kopin | 391.4K | 1.10% | — | 391.4K | — | 391.4K | HC, IN | United States of America | 2018-02-13 | ↗ |
| 14 | Empery Asset Management, LP | 134.4K | 0.38% | — | 134.4K | — | — | PN | Delaware | 2018-01-16 | ↗ |
| 15 | Martin D. Hoe | 134.4K | 0.38% | — | 134.4K | — | — | IN | Delaware | 2018-01-16 | ↗ |
| 16 | Ryan M. Lane | 134.4K | 0.38% | — | 134.4K | — | — | IN | Delaware | 2018-01-16 | ↗ |
| 17 | Capital Ventures International | — | 0.00% | — | — | — | — | CO | Cayman Islands | 2016-02-12 | ↗ |
| 18 | Heights Capital Management, Inc. | — | 0.00% | — | — | — | — | CO | Delaware | 2016-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
120.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+120,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018-06-06 | Yu John S | Director | A-Award | A | Common Stock | 120,000 | 0.00 | — | 120,250 | — | ↗ |
| 2016-12-31 | Gengos Andrew | Director | F-InKind | D | Common Stock | 3,284 | 2.05 | 6.7K | 5,249 | — | ↗ |
| 2016-06-17 | Yu John S | Director | A-Award | A | Stock Option (right to buy) | 156,750 | 0.24 | 37.6K | 156,750 | — | ↗ |
| 2016-06-17 | Titus Gary | Director / Officer | A-Award | A | Stock Option (right to buy) | 156,750 | 0.24 | 37.6K | 156,750 | — | ↗ |
| 2016-06-17 | Singhvi Rahul | Director | A-Award | A | Stock Option (right to buy) | 156,750 | 0.24 | 37.6K | 156,750 | — | ↗ |
| 2016-06-17 | SCHLOSSBERG MARK A | Director | A-Award | A | Stock Option (right to buy) | 156,750 | 0.24 | 37.6K | 156,750 | — | ↗ |
| 2016-06-17 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (right to buy) | 156,750 | 0.24 | 37.6K | 156,750 | — | ↗ |
| 2016-03-11 | Swanson Steven J | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2016-03-11 | Gringeri Anthony | Officer | A-Award | A | Stock Option (Right to Buy) | 225,000 | 0.33 | 74.3K | 225,000 | — | ↗ |
| 2016-03-11 | Gengos Andrew | Director / Officer | A-Award | A | Common Stock | 150,000 | 0.00 | — | 341,333 | — | ↗ |
| 2016-03-11 | FRACTOR DAVID | Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 70,000 | — | ↗ |
| 2015-11-30 | Gengos Andrew | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 0.44 | 4.4K | 47,000 | — | ↗ |
| 2015-09-28 | Yu John S | Director | F-InKind | D | Common Stock | 14,674 | 0.46 | 6.8K | 20,326 | — | ↗ |
| 2015-09-18 | Titus Gary | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 28,000 | — | ↗ |
| 2015-09-18 | Singhvi Rahul | Director | A-Award | A | Common Stock | 10,000 | 0.00 | — | 15,000 | — | ↗ |
| 2015-09-18 | SCHLOSSBERG MARK A | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-09-18 | LAPOINTE ANTHONY GREGG | Director | A-Award | A | Stock Option (Rt to Buy) | 40,000 | 0.47 | 18.8K | 40,000 | — | ↗ |
| 2015-06-26 | Yu John S | Director / Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 0.48 | 24.0K | 50,000 | — | ↗ |
| 2015-06-26 | Titus Gary | Director | A-Award | A | Stock Option (right to buy) | 75,000 | 0.48 | 36.0K | 75,000 | — | ↗ |
| 2015-06-26 | Singhvi Rahul | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 0.48 | 33.6K | 70,000 | — | ↗ |
| 2015-03-20 | Yu John S | Director / Officer | A-Award | A | Stock Option (Rt to Buy) | 100,000 | 0.57 | 57.0K | 100,000 | — | ↗ |
| 2015-03-20 | Gringeri Anthony | Officer | A-Award | A | Stock Option (Rt to Buy) | 112,500 | 0.57 | 64.1K | 112,500 | — | ↗ |
| 2015-03-20 | Gengos Andrew | Director / Officer | A-Award | A | Common Stock | 150,000 | 0.00 | — | 228,333 | — | ↗ |
| 2015-03-20 | FRACTOR DAVID | Officer | A-Award | A | Stock Option (Rt to Buy) | 50,000 | 0.57 | 28.5K | 50,000 | — | ↗ |
| 2015-03-06 | Swanson Steven J | Officer | A-Award | A | Stock Option (right to buy) | 350,000 | 0.59 | 206.5K | 350,000 | — | ↗ |
| 2015-02-18 | Swanson Steven J | Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-02-18 | Gringeri Anthony | Officer | P-Purchase | A | Common Stock | 30,000 | 0.60 | 18.0K | 66,000 | — | ↗ |
| 2015-02-18 | Gengos Andrew | Director / Officer | P-Purchase | A | Warrant to Purchase Common Stock | 28,933 | 0.66 | 19.1K | 28,933 | — | ↗ |
| 2015-02-18 | FRACTOR DAVID | Officer | P-Purchase | A | Common Stock | 16,667 | 0.60 | 10.0K | 41,667 | — | ↗ |
| 2014-08-21 | Gringeri Anthony | Officer | P-Purchase | A | Common Stock | 11,000 | 0.91 | 10.0K | 36,000 | — | ↗ |
| 2014-08-14 | Gengos Andrew | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-06-13 | Yu John S | Director / Officer | A-Award | A | Stock Option (right to buy) | 36,539 | 1.19 | 43.5K | 36,539 | — | ↗ |
| 2014-06-13 | Titus Gary | Director | A-Award | A | Stock Option (right to buy) | 47,500 | 1.19 | 56.5K | 47,500 | — | ↗ |
| 2014-06-13 | Singhvi Rahul | Director | A-Award | A | Stock Option (right to buy) | 51,154 | 1.19 | 60.9K | 51,154 | — | ↗ |
| 2014-06-13 | Kim Helen Susan | Director | A-Award | A | Stock Option (right to buy) | 40,193 | 1.19 | 47.8K | 40,193 | — | ↗ |
| 2014-06-13 | Chin Richard | Director | A-Award | A | Stock Option (right to buy) | 29,231 | 1.19 | 34.8K | 29,231 | — | ↗ |
| 2014-03-07 | Yu John S | Director / Officer | A-Award | A | Stock Option (right to buy) | 22,500 | 1.34 | 30.2K | 22,500 | — | ↗ |
| 2014-03-07 | Gringeri Anthony | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 1.34 | 100.5K | 75,000 | — | ↗ |
| 2014-03-07 | Gengos Andrew | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 1.34 | 268.0K | 200,000 | — | ↗ |
| 2014-03-07 | FRACTOR DAVID | Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 1.34 | 26.8K | 20,000 | — | ↗ |
| 2013-12-23 | Gringeri Anthony | Officer | P-Purchase | A | Common Stock | 25,000 | 0.87 | 21.6K | 25,000 | — | ↗ |
| 2013-12-20 | Titus Gary | Director | P-Purchase | A | Common Stock | 17,900 | 0.78 | 14.0K | 18,000 | — | ↗ |
| 2013-12-18 | Gengos Andrew | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-11-26 | COWELL RICHARD | Director | M-Exempt | A | Common Stock | 8,301 | 0.95 | 7.9K | 18,301 | — | ↗ |
| 2013-11-25 | Yu John S | Director / Officer | M-Exempt | A | Common Stock | 32,613 | 0.25 | 8.2K | 42,613 | — | ↗ |
| 2013-11-25 | COWELL RICHARD | Director | M-Exempt | D | Stock Option (right to buy) | 30,301 | 1.35 | 40.9K | 19,699 | — | ↗ |
| 2013-10-21 | Yu John S | Director / Officer | G-Gift | D | Common Stock | 36,006 | 0.00 | — | 10,000 | — | ↗ |
| 2013-10-18 | Yu John S | Director / Officer | S-Sale | D | Common Stock | 231,381 | 2.91 | 673.2K | 0 | — | ↗ |
| 2013-09-20 | Yu John S | Director / Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 2.70 | 135.0K | 50,000 | — | ↗ |
| 2013-09-20 | Titus Gary | Director | A-Award | A | Stock Option (right to buy) | 65,000 | 2.70 | 175.5K | 65,000 | — | ↗ |
| 2013-09-20 | Singhvi Rahul | Director | A-Award | A | Stock Option (right to buy) | 70,000 | 2.70 | 189.0K | 70,000 | — | ↗ |
| 2013-09-20 | Kim Helen Susan | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 2.70 | 135.0K | 50,000 | — | ↗ |
| 2013-09-20 | Gringeri Anthony | Officer | A-Award | A | Stock Option (right to buy) | 300,000 | 2.70 | 810.0K | 300,000 | — | ↗ |
| 2013-09-20 | Chin Richard | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 2.70 | 121.5K | 45,000 | — | ↗ |
| 2013-08-29 | Bender James G. | Officer | S-Sale | D | Common Stock | 900 | 3.00 | 2.7K | 100 | — | ↗ |
| 2013-08-28 | Bender James G. | Officer | S-Sale | D | Common Stock | 3,303 | 2.85 | 9.4K | 6,000 | — | ↗ |
| 2013-08-19 | Gringeri Anthony | Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-06-14 | Yu John S | Director / Officer | A-Award | D | Stock Option (right to buy) | 45,000 | 2.19 | 98.6K | 45,000 | — | ↗ |
| 2013-03-07 | Titus Gary | Director | A-Award | D | Stock Option (right to buy) | 21,945 | 2.72 | 59.7K | 21,945 | — | ↗ |
| 2013-03-07 | FRACTOR DAVID | Officer | A-Award | D | Stock Option (right to buy) | 64,000 | 2.72 | 174.1K | 64,000 | — | ↗ |
| 2013-03-07 | Bender James G. | Officer | A-Award | D | Stock Option (right to buy) | 80,000 | 2.72 | 217.6K | 80,000 | — | ↗ |
| 2012-12-28 | Titus Gary | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-12-03 | Gengos Andrew | Director / Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-09-24 | Yu John S | Director / Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 3.00 | 150.0K | 50,000 | — | ↗ |
| 2012-09-24 | Singhvi Rahul | Director | A-Award | A | Stock Option (right to buy) | 75,000 | 3.00 | 225.0K | 75,000 | — | ↗ |
| 2012-09-24 | Kim Helen Susan | Director | A-Award | A | Stock Option (right to buy) | 45,000 | 3.00 | 135.0K | 45,000 | — | ↗ |
| 2012-09-24 | Chin Richard | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 3.00 | 150.0K | 50,000 | — | ↗ |
| 2012-09-24 | COWELL RICHARD | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 3.00 | 180.0K | 60,000 | — | ↗ |
| 2012-08-02 | Chin Richard | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 2.94 | 29.4K | 10,000 | — | ↗ |
| 2012-06-11 | Bender James G. | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 3.42 | 256.5K | 75,000 | — | ↗ |
| 2012-06-01 | Bender James G. | Officer | S-Sale | D | Common Stock | 600 | 3.61 | 2.2K | 679 | — | ↗ |
| 2012-05-31 | Bender James G. | Officer | S-Sale | D | Common Stock | 200 | 3.94 | 788.00 | 7,679 | — | ↗ |
| 2012-05-25 | Yu John S | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2012-05-25 | Singhvi Rahul | Director | — | D | Common Stock | 0 | 0.00 | — | 5,000 | — | ↗ |
| 2012-05-25 | Singh Manish | Director / Officer | — | D | Stock Option (right to buy) | 270,000 | 2.25 | 607.5K | 0 | — | ↗ |
| 2012-05-25 | Kim Helen Susan | Director | — | D | Stock Option (right to buy) | 40,000 | 1.42 | 56.8K | 0 | — | ↗ |
| 2012-05-25 | FRACTOR DAVID | Officer | — | D | Stock Option (right to buy) | 42,000 | 2.25 | 94.5K | 0 | — | ↗ |
| 2012-05-25 | Chin Richard | Director | — | D | Stock Option (right to buy) | 22,500 | 2.71 | 61.0K | 0 | — | ↗ |
| 2012-05-25 | COWELL RICHARD | Director | — | D | Stock Option (right to buy) | 25,000 | 0.27 | 6.8K | 0 | — | ↗ |
| 2012-05-25 | Bender James G. | Officer | — | D | Common Stock | 0 | 0.00 | — | 14,679 | — | ↗ |
| 2012-05-25 | BRANDWYNNE JACQUELINE | Director | — | D | Stock Option (right to buy) | 50,000 | 1.15 | 57.5K | 0 | — | ↗ |
| 2012-01-13 | Singh Manish | Director / Officer | — | D | Warrant (right to buy) | 50,000 | 1.41 | 70.5K | 0 | — | ↗ |
| 2008-02-14 | BRANDWYNNE JACQUELINE | Director | — | D | Stock Option (right to buy) | 75,000 | 1.30 | 97.5K | 0 | — | ↗ |
| 2006-11-17 | Yu John S | Director / Officer | — | D | Stock Option (right to buy) | 5,933,424 | 1.00 | 5.93M | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
113.27M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Irach Taraporewala | Chief Executive Officer, President & Director | 265.6K | — |
| Wayne I. Danson | Chief Financial Officer & Treasurer | 150.0K | male |
| Eli Goldberger | Founder, Chairman & Chief Operating Officer | — | male |
| Shalom Z. Hirschman | Co-Founder, Chief Scientific Officer & Medical Director | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IMUC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
